ARTICLE | Clinical News
N91115: Phase II started
May 23, 2016 7:00 AM UTC
Nivalis began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 400 mg oral N91115 twice daily for 12 weeks plus Kalydeco ivacaftor in about 20 patients. The trial is enrolling adul...